Who are SKYRIZI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risankizumab (RISA), Mirikizumab (MIR), Mirikizumab - Intravenous (IV), Mirikizumab - SC, Mirikizumab - IV, Ilumya Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/skyrizi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

SKYRIZI — Competitive Intelligence Brief

SKYRIZI (SKYRIZI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-23 inhibitor monoclonal antibody. Area: Immunology/Dermatology.

marketed IL-23 inhibitor monoclonal antibody IL-23 (p19 subunit) Immunology/Dermatology Biologic Live · refreshed every 30 min

Target snapshot

SKYRIZI (SKYRIZI) — Chong Kun Dang Pharmaceutical. SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SKYRIZI TARGET	SKYRIZI	Chong Kun Dang Pharmaceutical	marketed	IL-23 inhibitor monoclonal antibody	IL-23 (p19 subunit)
Risankizumab (RISA)	Risankizumab (RISA)	Caja Costarricense de Seguro Social	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab (MIR)	Mirikizumab (MIR)	Alimentiv Inc.	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab - Intravenous (IV)	Mirikizumab - Intravenous (IV)	University of North Carolina, Chapel Hill	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab - SC	Mirikizumab - SC	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab - IV	Mirikizumab - IV	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Ilumya Injectable Product	Ilumya Injectable Product	Psoriasis Treatment Center of Central New Jersey	marketed	IL-23 inhibitor (monoclonal antibody)	IL-23 p19 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-23 inhibitor monoclonal antibody class)

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 2 drugs in this class
Caja Costarricense de Seguro Social · 1 drug in this class
Chong Kun Dang Pharmaceutical · 1 drug in this class
Janssen Pharmaceutical K.K. · 1 drug in this class
Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class
Sun Pharmaceutical Industries Limited · 1 drug in this class
University of Calgary · 1 drug in this class
Alimentiv Inc. · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SKYRIZI — Competitive Intelligence Brief. https://druglandscape.com/ci/skyrizi. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab